Fresenius Kabi has entered into a definitive agreement to purchase Fenwal, a provider of separation technologies for blood and cell collection and therapy.
Under the acquisition, both the companies are working together to bring their customers various products and services, while continuing to increase their pace of product development and geographic expansion.
Fresenius Kabi chairman and chief executive officer Rainer Baule said Fenwal has built a leadership position centered on separation technology used to collect and process blood and to treat disease.
"Like Fresenius Kabi, Fenwal has a unique and long history serving health care, productive relationships with customers and researchers, and a rich pipeline of new products that are essential to patients and those who care for them," Baule added.
Fenwal president and chief executive officer Ron Labrum said the products, services, technologies and cultures of both companies fit extremely well together.
"We are committed to assuring a smooth integration with Fresenius Kabi and to bringing our customers even more value as a result of this unique combination," Labrum added.
The terms of Fresenius Kabi’s deal with Fenwal have not been disclosed.
The transaction, which is expected to be completed by the end of 2012, is subject to customary conditions.